These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
186 related articles for article (PubMed ID: 22672259)
1. Serum concentrations of vascular endothelial growth factor in an infant treated with ranibizumab for retinopathy of prematurity. Hoerster R; Muether P; Dahlke C; Mehler K; Oberthür A; Kirchhof B; Fauser S Acta Ophthalmol; 2013 Feb; 91(1):e74-5. PubMed ID: 22672259 [No Abstract] [Full Text] [Related]
2. Bilateral effect of unilateral bevacizumab injection in retinopathy of prematurity. Karaca C; Oner AO; Mirza E; Polat OA; Sahiner M JAMA Ophthalmol; 2013 Aug; 131(8):1099-101. PubMed ID: 23744183 [No Abstract] [Full Text] [Related]
3. Fluorescein angiography of aggressive posterior retinopathy of prematurity treated with intravitreal anti-VEGF in large preterm babies. Park SW; Jung HH; Heo H Acta Ophthalmol; 2014 Dec; 92(8):810-3. PubMed ID: 24909062 [No Abstract] [Full Text] [Related]
4. A rare association of intravitreal bevacizumab injection with double ridge formation in retinopathy of prematurity. Yaz Y; Erol N; Gursoy H; Basmak H; Bilgec MD J Pediatr Ophthalmol Strabismus; 2014 Oct; 51 Online():e66-8. PubMed ID: 25333243 [TBL] [Abstract][Full Text] [Related]
5. Short-term outcome after intravitreal ranibizumab injections for the treatment of retinopathy of prematurity. Castellanos MA; Schwartz S; García-Aguirre G; Quiroz-Mercado H Br J Ophthalmol; 2013 Jul; 97(7):816-9. PubMed ID: 23221964 [TBL] [Abstract][Full Text] [Related]
6. FLUORESCEIN ANGIOGRAPHIC EVALUATION OF PERIPHERAL RETINAL VASCULATURE AFTER PRIMARY INTRAVITREAL RANIBIZUMAB FOR RETINOPATHY OF PREMATURITY. Harper CA; Wright LM; Young RC; Read SP; Chang EY Retina; 2019 Apr; 39(4):700-705. PubMed ID: 29300248 [TBL] [Abstract][Full Text] [Related]
7. Retinal detachment despite aggressive management of aggressive posterior retinopathy of prematurity. Suk KK; Berrocal AM; Murray TG; Rich R; Major JC; Hess D; Johnson RA J Pediatr Ophthalmol Strabismus; 2010 Dec; 47 Online():e1-4. PubMed ID: 21175113 [TBL] [Abstract][Full Text] [Related]
8. Intravitreal ranibizumab monotherapy to treat retinopathy of prematurity zone II, stage 3 with plus disease. Menke MN; Framme C; Nelle M; Berger MR; Sturm V; Wolf S BMC Ophthalmol; 2015 Mar; 15():20. PubMed ID: 25886603 [TBL] [Abstract][Full Text] [Related]
9. Favorable outcomes in the treatment of aggressive posterior retinopathy of prematurity. Sahinoglu-Keskek N; Akkoyun I; Torer B Eur J Ophthalmol; 2021 Jan; 31(1):179-183. PubMed ID: 31718282 [TBL] [Abstract][Full Text] [Related]
10. What is the optimal dosage for intravitreal bevacizumab for retinopathy of prematurity? Spandau U Acta Ophthalmol; 2013 Mar; 91(2):e154. PubMed ID: 22989079 [No Abstract] [Full Text] [Related]
11. Intravitreal anti-vascular endothelial growth factor treatment for retinopathy of prematurity: comparison between Ranibizumab and Bevacizumab. Chen SN; Lian I; Hwang YC; Chen YH; Chang YC; Lee KH; Chuang CC; Wu WC Retina; 2015 Apr; 35(4):667-74. PubMed ID: 25462435 [TBL] [Abstract][Full Text] [Related]
12. Vascular endothelial growth factor plasma levels before and after treatment of retinopathy of prematurity with ranibizumab. Zhou Y; Jiang Y; Bai Y; Wen J; Chen L Graefes Arch Clin Exp Ophthalmol; 2016 Jan; 254(1):31-6. PubMed ID: 25851862 [TBL] [Abstract][Full Text] [Related]
13. Dramatic regression of persistent tunica vasculosa lentis associated with retinopathy of prematurity following treatment with intravitreal bevacizumab. Goldman DR; Baumal CR J Pediatr Ophthalmol Strabismus; 2013 Jun; 50 Online():e27-9. PubMed ID: 24601434 [TBL] [Abstract][Full Text] [Related]
14. [The clinical study on intravitreous injection of ranibizumab for aggressive posterior retinopathy of prematurity]. Tian R; Zhang G; Tang S; Guo J; Tan W Zhonghua Yan Ke Za Zhi; 2015 Nov; 51(11):822-5. PubMed ID: 26850583 [TBL] [Abstract][Full Text] [Related]
15. Intravitreal bevacizumab for retinopathy of prematurity: refractive error results. Harder BC; Schlichtenbrede FC; von Baltz S; Jendritza W; Jendritza B; Jonas JB Am J Ophthalmol; 2013 Jun; 155(6):1119-1124.e1. PubMed ID: 23490192 [TBL] [Abstract][Full Text] [Related]
16. Long-term effect of antiangiogenic therapy for retinopathy of prematurity up to 5 years of follow-up. Martínez-Castellanos MA; Schwartz S; Hernández-Rojas ML; Kon-Jara VA; García-Aguirre G; Guerrero-Naranjo JL; Chan RV; Quiroz-Mercado H Retina; 2013 Feb; 33(2):329-38. PubMed ID: 23099498 [TBL] [Abstract][Full Text] [Related]
17. Early refractive outcome after intravitreous bevacizumab for retinopathy of prematurity. Harder BC; von Baltz S; Schlichtenbrede FC; Jonas JB Arch Ophthalmol; 2012 Jun; 130(6):800-1. PubMed ID: 22801850 [No Abstract] [Full Text] [Related]
18. Efficacy of ultra-low-dose (0.1 mg) ranibizumab intravitreal injection for treatment of prethreshold type 1 retinopathy of prematurity: A case series. Ahmed IS; Hadi AM; Hassan HH Eur J Ophthalmol; 2020 Jan; 30(1):40-47. PubMed ID: 30428702 [TBL] [Abstract][Full Text] [Related]